The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new ...
Despite Medicare's efforts to expand benefits and improve affordability, many seniors continue to face significant barriers ...
Stay updated on market trends for VRTX. Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies Vertex's Journavx, a new non-opioid pain drug ...
In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback